Jefferies Group set a $153.00 target price on Johnson & Johnson (NYSE:JNJ) in a research report released on Friday. The firm currently has a buy rating on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s Q1 2018 earnings at $2.00 EPS and FY2018 earnings at $8.16 EPS.
Several other research firms have also recently weighed in on JNJ. Wells Fargo restated an outperform rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Vetr upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $150.89 price objective for the company in a research report on Thursday, January 11th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock a hold rating in a research report on Monday, January 22nd. Royal Bank of Canada restated a buy rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Finally, BTIG Research restated a sell rating and issued a $110.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $144.03.
JNJ stock opened at $131.76 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a market capitalization of $350,440.66, a P/E ratio of 18.05, a P/E/G ratio of 2.08 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the previous year, the company posted $1.58 EPS. Johnson & Johnson’s revenue was up 11.5% on a year-over-year basis. sell-side analysts forecast that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.22% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the company. Goodman Financial Corp acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $104,000. Harding Loevner LP acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $106,000. Stelac Advisory Services LLC acquired a new position in Johnson & Johnson in the 4th quarter worth $108,000. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. Finally, Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson in the 2nd quarter worth $124,000. 67.23% of the stock is owned by institutional investors.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/jefferies-group-reiterates-153-00-price-target-for-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.